Background: Patients diagnosed with COVID-19 have an increased risk of thromboembolic events, including pulmonary embolism and deep vein thrombosis (DVT). In addition, COVID-19 patients with increased coagulation parameters such as D-dimer, fibrin degradation products, prothrombin time, and activated partial thromboplastin ...
Background: The optimal approach to risk stratifying patients for pulmonary embolism (PE) remains elusive. Multiple decision instruments are available with varying degrees of complexity and acceptance among emergency medicine clinicians (Wells, Geneva, PERC, YEARS, age-adjusted D-dimer). The 2018 ACEP clinical ...
Background: Patients with COVID-19 are at increased risk from thromboembolic phenomena. Patient-specific factors such as comorbidities and immobility have been linked to thrombosis. Disease-specific factors such as virus-induced endothelial changes and cytokine storm may also be triggers. Furthermore, patients with elevated ...
In this 20-minute presentation from Rebellion in EM 2021, Dr. J Scott Wieters, MD discusses the evidence for and against the use of tranexamic acid for hemorrhage alleviation in gastrointestinal bleeding by doing a critical appraisal of the HALT-IT ...
Background: Patients with COVID-19 are at a high risk for the development of venous thromboembolic disease . Alveolar capillary microthrombi appear to be 9x more prevalent in patients with COVID-19 compared to H1N1. As a result, enhanced-dose anticoagulation ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
